Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Introduction: In the phase 3 KEYNOTE-604 study (NCT03066778), pembrolizumab plus etoposide and platinum chemotherapy (EP) significantly (p = 0.0023) improved progression-free survival versus placebo plus EP in previously untreated extensive-stage SCLC (ES-SCLC). We present health-related quality of...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Hye Ryun Kim, MD, PhD, Mark M. Awad, MD, PhD, Alejandro Navarro, MD, Maya Gottfried, MD, Solange Peters, MD, PhD, Tibor Csőszi, MD, Parneet K. Cheema, MD, Delvys Rodriguez-Abreu, MD, PhD, Mirjana Wollner, MD, James Chih-Hsin Yang, MD, PhD, Julien Mazieres, MD, PhD, Francisco J. Orlandi, MD, Alexander Luft, MD, PhD, Mahmut Gümüş, MD, Terufumi Kato, MD, Gregory P. Kalemkerian, MD, Yiwen Luo, PhD, Melissa L. Santorelli, PhD, MPH, M. Catherine Pietanza, MD, Charles M. Rudin, MD, PhD
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2023-11-01
Sarja:	JTO Clinical and Research Reports
Aiheet:	Pembrolizumab Chemotherapy Extensive-stage small-cell lung cancer Health-related quality of life Patient-reported outcomes
Linkit:	http://www.sciencedirect.com/science/article/pii/S2666364323001157
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!